Muneo Takatani

Tomomi Ikemoto; Tetsuji Kawamoto; Hiroki Wada; Toru Ishida; Tatsuya Ito; Yasushi Isogami; Yoshiko Miyano; Yukio Mizuno; Kiminori Tomimatsu; Kazumasa Hamamura; Muneo Takatani; Mitsuhiro Wakimasu

Abstract The 5-thia-1,8b-diazaacenaphthylenes ( 2 and its ester, 8 ) are new cyclazines, in which a paramagnetic ring is present in the peripheral 12π-electron ring system. Three convenient methods of preparing 8 have been developed. One involved thioglycolation of a new compound, 5-fluoroimidazo[1,2- a ]pyridine ( 6b ), followed by the Duff reaction gave 8 in 64% yield without chromatographic purification.

Tomomi Ikemoto; Tetsuji Kawamoto; Kiminori Tomimatsu; Muneo Takatani; Mitsuhiro Wakimasu

Abstract A convenient synthesis of the chronic renal disease agent, trifluoro-N-[4-(3-oxo-3,5-dihydro-4H-1,4,8b-triazaacenaphthylen-4-yl)butyl]methanesulfonamide (1a), for large scale has been developed via ethyl 5-(chloromethyl)imidazo[1,2-a]pyridine-3-carboxylate (3), which was given by the regioselective chlorination of ethyl 5-methylimidazo[1,2-a]pyridine-3-carboxylate (6) with N-chlorosuccinimide (NCS) using AcOEt as a solvent in 83% yield. The condensation of 3 and primary amines gave 4,5-dihydro-3H-1,4,8b-triazaacenaphthylen-3-one derivatives (1) in good yields. The present synthesis of 1a was accomplished in five steps from 2-amino-6-methylpyridine (4) without requiring a chromatographic method.

Tetsuji Kawamoto; Kiminori Tomimatsu; Tomomi Ikemoto; Hidenori Abe; Kazumasa Hamamura; Muneo Takatani

Novel 5-thia-1-azacycl[3.3.2]azine derivatives 1 , 5-thia-1,8b-diazaacenaphthylenes, have successfully been prepared. An X-ray crystallographic analysis of 1c revealed that the 5-thia-1-azacycl[3.3.2]azine ring system adopts a planar structure as to the internal ring nitrogen atom. The 1 H NMR spectrum for unsubstituted ring system 1d implies contribution of a paramagnetic ring current in the peripheral 12π-electron ring system. Also, 3 H -1,4-diazacycl[3.3.2]azine derivatives, 4-benzyl-4,5-dihydro-3 H -1,4,8b-triazaacenaphthylen(e)-3-ones 2 and -3,5-diones 3 were synthesized with high efficiency via 3-(trichloroacetyl)imidazo[1,2- a ]pyridine derivatives as new useful synthetic intermediates.

Muneo Takatani; Barry Kenny; Nick Hird

Takeda (http://www.takeda.com) is one of the oldest Pharmaceutical companies in the world and has been the largest Japanese Pharmaceutical company for over a decade. Although many of its operations such as development and marketing have been conducted on a global basis for a number of years, research has historically been focused on in-house activities inside Japan, which have a successful track record in generating pioneer blockbuster drugs. To meet the ever-increasing challenge of maintaining a robust pipeline and a continuous stream of INDs, Takeda has embarked on a program to globalize its internal drug discovery capability through the integration of world-class research entities. We outline the strategies, opportunities and challenges of building a global research network from the perspective of a Japanese Pharmaceutical company.

Muneo Takatani; Taketoshi Saijo; Kiminori Tomimatsu

Muneo Takatani; Yoshio Kozai; Kiminori Tomimatsu; Yumiko Shibouta

Muneo Takatani; Hitoshi Ikeda; Kyoko Iida; Hidenori Abe

Muneo Takatani; Yumiko Shibouta; Kiminori Tomimatsu; Tetsuji Kawamoto

Susumu Tsushima; Muneo Takatani; Kohei Nishikawa

Yumiko Shibouta; Yasuo Sugiyama; Tetsuji Kawamoto; Muneo Takatani